-61%

est. 2Y upside i

HealthcareSeries C

Verse Medical is building the modern software infrastructure to make it happen. We're a well-funded Series C company (backed by General Catalyst, SignalFire, and Sapphire Ventures) on a mission to heal a fragmented system. Our platform connects the dots between providers, payors, and patients, ensuring people get the high-quality care they need, reliably and right where they live.

Rank

#2412

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Low

Verse Medical, a Series C HealthTech company with a $735.18M valuation, offers moderate upside potential driven by its AI-enabled platform in the growing in-home care market.

Last updated: March 10, 2026

Bull (20%)+200%

Verse Medical's AI-enabled platform achieves significant market penetration by securing key partnerships with major health systems and payors, expanding its reach beyond DME into broader in-home care coordination. This drives revenue to an estimated $150M by 2028, justifying a $2.20B valuation at a premium multiple in a strong HealthTech M&A environment.

Base (35%)+60%

Verse Medical continues to grow steadily, capturing market share in the fragmented DME and in-home care coordination space, but faces ongoing competition from incumbents like WellSky. Revenue grows to an estimated $80M by 2028, leading to an acquisition at a $1.18B valuation, representing a moderate return for equity holders.

Bear (45%)-50%

Increased competitive pressure from WellSky and other established players, who aggressively integrate AI and expand their home care offerings, limits Verse Medical's growth and pricing power. Revenue stalls at an estimated $25M, leading to a down round or acquisition at a significantly reduced valuation of $367.59M, severely impacting common stock value due to the preference stack.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Investors hold $109.43M in liquidation preferences ahead of common stock.

Dilution Risk

moderate

As a Series C company, expect further dilution from potential future funding rounds before a liquidity event.

Secondary Liquidity

limited

Accredited investors may have limited opportunities to sell shares on platforms like Forge, but it is not a public market.

Other — 4 roles

View all 4 open roles at Verse →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Verse's data — designed to show you've done your homework.

  • 1

    “How does Verse Medical plan to maintain its competitive edge and differentiate its modern technology-first approach against established and well-funded incumbents like WellSky, especially as they also integrate AI into their offerings?”

  • 2

    “Given the estimated $50M ARR and the large TAM of $24.2B, what are the key strategies for accelerating market penetration and scaling revenue significantly over the next 2-3 years, particularly in new geographic markets or service lines?”

  • 3

    “With a Series C valuation of $735.18M and total funding of $109.43M, what is the company's anticipated timeline and preferred path to a liquidity event (e.g., IPO or acquisition), and how does the preference stack impact employee equity value?”

Community

Valuation Sentiment

Our model estimates -61% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.